Luka Lezaic1, Aljaz Socan1, Gregor Poglajen2, Petra Kolenc Peitl1, Matjaz Sever3, Marko Cukjati4, Peter Cernelc3, Joseph C Wu5, François Haddad5, Bojan Vrtovec6. 1. Department for Nuclear Medicine, University Medical Centre (UMC), Ljubljana, Slovenia. 2. Advanced Heart Failure and Transplantation Centre, Department of Cardiology, UMC Ljubljana, Ljubljana, Slovenia. 3. Department of Hematology, UMC Ljubljana, Ljubljana, Slovenia. 4. National Blood Transfusion Institute, Ljubljana, Slovenia. 5. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA. 6. Department for Nuclear Medicine, University Medical Centre (UMC), Ljubljana, Slovenia; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA. Electronic address: bvrtovec@stanford.edu.
Abstract
BACKGROUND: We investigated the effects of intracoronary transplantation of CD34(+) cells on myocardial perfusion in patients with nonischemic dilated cardiomyopathy (DCM). METHODS AND RESULTS: We enrolled 21 patients with DCM (left ventricular ejection fraction [LVEF] <40%, New York Heart Association functional class III) who underwentperipheral stem cell mobilization with granulocyte-colony stimulating factor (G-CSF). CD34(+) cells were collected by means of apheresis. Patients underwent myocardial perfusion imaging, and CD34(+) cells were injected in the coronary artery supplying viable segments with reduced myocardial perfusion and regional dysfunction. Myocardial perfusion imaging was repeated 6 months later. Clinical response to stem cell therapy was predefined as a change in LVEF >5%. The majority of patients were men (81%) with an overall mean age 53 ± 9 years, LVEF 25 ± 5%, and 6-minute walking distance 354 ± 71 m. Myocardial perfusion defects at rest were observed in 86% of patients and were more common in the left anterior descending territory (50%). At 6 months' follow-up, there was a significant improvement in rest myocardial perfusion scores (6.3 ± 5.8 vs 3.1 ± 4.3; P < .001), LVEF (25 ± 7% vs 29 ± 8%; P = .005), and 6-minute walking distance (354 ± 71 m vs 404 ± 91 m; P < .001). Responders to stem cell therapy had lower summed rest perfusion score at both baseline (3.2 ± 3.0 vs 9.1 ± 6.3; P = .015) and follow-up (1.0 ± 1.5 vs 5.0 ± 5.1; P = .028). CONCLUSIONS:CD34(+) cell transplantation may lead to improved myocardial perfusion in patients with nonischemic DCM. Patients with less severe myocardial perfusion defects at baseline may have an increased likelihood to respond to intracoronary CD34(+) cell transplantation.
RCT Entities:
BACKGROUND: We investigated the effects of intracoronary transplantation of CD34(+) cells on myocardial perfusion in patients with nonischemic dilated cardiomyopathy (DCM). METHODS AND RESULTS: We enrolled 21 patients with DCM (left ventricular ejection fraction [LVEF] <40%, New York Heart Association functional class III) who underwent peripheral stem cell mobilization with granulocyte-colony stimulating factor (G-CSF). CD34(+) cells were collected by means of apheresis. Patients underwent myocardial perfusion imaging, and CD34(+) cells were injected in the coronary artery supplying viable segments with reduced myocardial perfusion and regional dysfunction. Myocardial perfusion imaging was repeated 6 months later. Clinical response to stem cell therapy was predefined as a change in LVEF >5%. The majority of patients were men (81%) with an overall mean age 53 ± 9 years, LVEF 25 ± 5%, and 6-minute walking distance 354 ± 71 m. Myocardial perfusion defects at rest were observed in 86% of patients and were more common in the left anterior descending territory (50%). At 6 months' follow-up, there was a significant improvement in rest myocardial perfusion scores (6.3 ± 5.8 vs 3.1 ± 4.3; P < .001), LVEF (25 ± 7% vs 29 ± 8%; P = .005), and 6-minute walking distance (354 ± 71 m vs 404 ± 91 m; P < .001). Responders to stem cell therapy had lower summed rest perfusion score at both baseline (3.2 ± 3.0 vs 9.1 ± 6.3; P = .015) and follow-up (1.0 ± 1.5 vs 5.0 ± 5.1; P = .028). CONCLUSIONS:CD34(+) cell transplantation may lead to improved myocardial perfusion in patients with nonischemic DCM. Patients with less severe myocardial perfusion defects at baseline may have an increased likelihood to respond to intracoronary CD34(+) cell transplantation.
Authors: Arshed A Quyyumi; Alejandro Vasquez; Dean J Kereiakes; Marc Klapholz; Gary L Schaer; Ahmed Abdel-Latif; Stephen Frohwein; Timothy D Henry; Richard A Schatz; Nabil Dib; Catalin Toma; Charles J Davidson; Gregory W Barsness; David M Shavelle; Martin Cohen; Joseph Poole; Thomas Moss; Pamela Hyde; Anna Maria Kanakaraj; Vitaly Druker; Amy Chung; Candice Junge; Robert A Preti; Robin L Smith; David J Mazzo; Andrew Pecora; Douglas W Losordo Journal: Circ Res Date: 2016-11-07 Impact factor: 17.367
Authors: Bojan Vrtovec; Matjaz Sever; Mojca Jensterle; Gregor Poglajen; Andrej Janez; Nika Kravos; Gregor Zemljic; Marko Cukjati; Peter Cernelc; François Haddad; Joseph C Wu; Ulrich P Jorde Journal: Stem Cells Transl Med Date: 2016-03-29 Impact factor: 6.940
Authors: Mojca Bervar; Mirta Kozelj; Gregor Poglajen; Matjaz Sever; Gregor Zemljic; Sabina Frljak; Marko Cukjati; Peter Cernelc; François Haddad; Bojan Vrtovec Journal: Stem Cells Transl Med Date: 2017-03-11 Impact factor: 6.940
Authors: Andraz Cerar; Gregor Zemljic; Sabina Frljak; Martina Jaklic; Gregor Poglajen; Matjaz Sever; Marko Cukjati; Bojan Vrtovec Journal: Cell Transplant Date: 2018-07-05 Impact factor: 4.064
Authors: Sabina Frljak; Martina Jaklic; Gregor Zemljic; Andraz Cerar; Gregor Poglajen; Bojan Vrtovec Journal: Stem Cells Transl Med Date: 2018-02 Impact factor: 6.940